Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial (Q34222016)

31 July 2017

Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial (English)

1 reference

multicenter clinical trial

31 July 2017

0 references

1 reference

1 reference

1

Erica A Eugster

1 reference

31 July 2017

Stephen D Rubin

2

1 reference

31 July 2017

Edward O Reiter

3

1 reference

31 July 2017

Paul Plourde

4

1 reference

31 July 2017

Hann-Chang Jou

5

1 reference

31 July 2017

Ora H Pescovitz

6

1 reference

31 July 2017

McCune-Albright Study Group

7

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

The Journal of Pediatrics

31 July 2017

1 reference

31 July 2017

143

1 reference

31 July 2017

1

1 reference

31 July 2017

60-66

1 reference

Syndrome Characterized by Osteitis Fibrosa Disseminata, Areas of Pigmentation and Endocrine Dysfunction, with Precocious Puberty in Females

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Activating mutations of the stimulatory G protein in the McCune-Albright syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Ovarian function in girls with McCune-Albright syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Dynamics of ovarian function in an adult woman with McCune--Albright syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

McCune-Albright syndrome: a longitudinal clinical study of 32 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

High-affinity anti-oestrogen binding site distinct from the oestrogen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2803%2900128-8

10.1016/S0022-3476(03)00128-8

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference